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Abstract [word count 247] 
Aims 
Evaluate efficacy and hypoglycaemia according to concomitant oral antidiabetes drug (OAD) in 
people with type 2 diabetes initiating insulin glargine 100 U/mL (Gla-100) or neutral protamine 
Hagedorn insulin (NPH) once daily. 
Methods  
Four studies (target fasting plasma glucose [FPG] ≤100 mg/dL [≤5.6 mmol/L]; duration ≥24 
weeks) were included. Standardised data from 2091 subjects (Gla-100, n=1024; NPH, n=1067) 
were analysed. Endpoints included: HbA1c and FPG change; glycaemic target achievement; 
hypoglycaemia; weight change and insulin dose.  
Results  
Mean HbA1c and FPG reductions were similar with Gla-100 and NPH regardless of concomitant 
OAD (P=0.184 and P=0.553, respectively) and similar proportions of subjects achieved HbA1c 
<7.0% (P=0.603). There was a trend for more subjects treated with Gla-100 achieving FPG 
≤100mg/dL vs NPH (RR 1.09 [95% CI 0.97-1.23]; P=0.135). Plasma glucose confirmed (<70 
mg/dL) overall and nocturnal hypoglycaemia incidences and rates were lower with Gla-100 
versus NPH (overall: RR 0.93 [95% CI 0.87-1.00]; P=0.041; nocturnal RR 0.73 [95% CI 0.65-
0.83]; P<0.001). After 24 weeks, weight gain and insulin doses were higher with Gla-100 versus 
NPH (2.7 kg vs 2.3 kg, P=0.009 and 0.42 U/kg vs 0.39 U/kg; P=0.003, respectively). Insulin 
doses were higher when either insulin was added to sulfonylurea alone. 
Conclusions  
Pooled results from treat-to-target trials in insulin-naïve people with type 2 diabetes demonstrate 
a significantly lower overall and nocturnal hypoglycaemia risk across different plasma glucose 
definitions with Gla-100 versus NPH at similar glycaemic control. OAD therapy co-administered 
with Gla-100 or NPH impacts glycaemic control and overall nocturnal hypoglycaemia risk.  
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1. Introduction  
People diagnosed with type 2 diabetes (T2DM) usually begin treatment with an oral agent, 
principally metformin or, if contraindicated, a sulfonylurea, dipeptidyl peptidase-4 (DPP-4) 
inhibitor, or insulin sensitizer [1, 2]. However, because it is a progressive disease, over time many 
people with T2DM will require the addition of insulin therapy to avoid hyperglycaemia [3]. 
Guidelines recommend the addition of basal insulin for those not meeting their individual HbA1c 
targets with current therapy [1, 2]. The options for providing basal insulin supplementation 
include basal insulin analogues (insulin glargine 100 U/mL [Gla-100] and 300 U/mL, insulin 
detemir, insulin degludec) recommended for once-daily dosing, and neutral protamine Hagedorn 
(NPH) insulin, an intermediate-acting basal insulin that is conventionally dosed once or twice 
daily [4]. In general, the longer-acting basal insulin analogues are preferred over intermediate-
acting NPH insulin because they provide a more physiological pattern of insulin release with less 
variability throughout the day, and are associated with lower rates of nocturnal and interprandial 
hypoglycaemia and a reduced requirement for self-monitoring of blood glucose [2, 4, 5].  
 
Hypoglycaemia is of particular concern for people with T2DM being treated with insulin (as well 
as certain oral antidiabetes drugs [OADs], mainly sulfonylureas and glinides), as it undermines 
confidence in their treatment, contributes to lost productivity, and has been associated with 
increased mortality [1, 2]. Additionally, concerns about hypoglycaemia may lead clinicians, and 
people managing their own T2DM, to under-dose basal insulin and thus fail to achieve optimal 
glycaemic control [6]. Therefore, minimising the risk of hypoglycaemia is crucial in the 
management of T2DM, and choosing a basal insulin that provides good glycaemic control with a 
reduced risk of hypoglycaemia is a key principle of achieving optimal care [1, 2].  
 
The aim of this analysis was to compare the initiation of Gla-100 or NPH insulin in people with 
T2DM inadequately controlled on existing OADs, using pooled, standardised subject-level data 
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solely derived from randomised, controlled, treat-to-target trials in order to evaluate outcomes 
according to concomitant OAD therapy. This may assist healthcare professionals in deciding the 
best course of action when initiating patients on basal insulin currently uncontrolled on various 
background OAD regimens. Combining subject-level data increases statistical power compared 
with individual studies, and is associated with less bias than the pooling of summary data from 
individual randomised controlled trials [7]. Data are presented for three different timeframes: the 
entire treatment period (Week 0–24), the titration phase (Week 0–12), and the maintenance phase 
(Week 12–24). 
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2. Methods 
2.1. Study Selection 
Only prospective phase IIIa/b or phase IV, randomised, controlled, treat-to-target trials comparing 
Gla-100 with NPH insulin, each given once-daily at bedtime, targeting FPG levels ≤100 mg/dL 
(≤5.6 mmol/L), and with a study duration ≥24 weeks were eligible for inclusion in this analysis. 
We initially identified seven studies [8–14], all of which were conducted by the manufacturer of 
Gla-100 (Sanofi, Paris, France and predecessor companies). Three trials were subsequently 
excluded because the FPG target in these trials was >100 mg/L [8, 9, 13]. Details of the studies 
included and excluded from the analysis are presented in Supplementary Table 1. 
 
2.2 Outcomes 
Glycaemic control was evaluated by determining mean HbA1c and FPG levels at baseline and 
change from baseline to Week 12 and to Week 24. The proportions of subjects achieving an 
HbA1c <7.0% (<53 mmol/mol) or <6.5% (<47.5 mmol/mol) or FPG <100 mg/dL (<5.6 mmol/L) 
at Week 12 and at Week 24 also were assessed. Both the incidence and event rates of overall, 
nocturnal, and severe hypoglycaemia were assessed during the entire treatment period and during 
titration and maintenance phases of the study. Overall hypoglycaemic events were defined as 
those with confirmed plasma glucose <70 mg/dL (<3.9 mmol/L) or <56 mg/dL (<3.1 mmol/L) or 
requiring third-party assistance. Nocturnal hypoglycaemic events were defined as those with 
confirmed plasma glucose <70 mg/dL or <56 mg/dL, occurring between the times of 00:01 and 
05:59. Severe hypoglycaemic events were defined as those events requiring third-party assistance 
together with confirmed plasma glucose <36 mg/dL (<2.0 mmol/L). In addition, composite 
efficacy and hypoglycaemia endpoints, including the proportion of subjects achieving an HbA1c 
<7.0% or <6.5% or a FPG ≤100 mg/dL without hypoglycaemia, also were assessed. Insulin dose, 
change in body weight, and the number needed to harm (NNH; the average number of people to 
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be treated for one additional person to experience a hypoglycaemic event if NPH insulin is used 
rather than Gla-100) were also calculated. 
 
2.3 Statistical Analysis 
Data from the studies were pooled and analysed within subpopulations determined by the 
specified background OAD therapies; i.e. metformin plus a sulfonylurea or a sulfonylurea alone. 
Subjects were excluded from the analysis if they took antidiabetes treatments other than 
metformin or a sulfonylurea at any time during the analysis period (e.g. thiazolidinediones 
[TZDs], glinides, DPP-4 inhibitors, sodium-glucose cotransporter-2 [SGLT2] inhibitors, alpha-
glucosidase inhibitors or another insulin which was not part of study medication). The safety 
population (all randomised subjects who received ≥1 dose of Gla-100 or NPH insulin and OADs 
within the subpopulation of interest) were included in all analyses. Continuous efficacy endpoints 
of HbA1c and FPG were analysed using generalised linear models with adjustments for OAD 
group (when applicable), study, and baseline value. For the comparative analyses, two-sided 95% 
confidence intervals (CIs) and P values were estimated for the group differences. For the 
outcomes of achievement of HbA1c or FPG targets, odds ratios (ORs) and 95% CIs were derived 
from a logistic binomial regression model, with baseline value as a covariate and treatment 
combination as a factor, including only those subjects not already at target at baseline (or Week 
12 for the assessment of the maintenance phase).  
 
The incidence and event rates of hypoglycaemia were adjusted for baseline subject 
characteristics. The proportion of subjects with ≥1 hypoglycaemic event (incidence) for Gla-100 
or NPH insulin within each OAD treatment group was analysed using a generalised linear logistic 
regression model with fixed-effect terms for age, baseline BMI, duration of diabetes, treatment, 
and OAD treatment group. In addition, the overall annualised rate (event rate per patient-year) of 
hypoglycaemic events was estimated and analysed based on negative binomial regression, also 
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with age, baseline BMI, duration of diabetes treatment, and OAD treatment group included as 
factors. Relative risk and rate ratios (with associated 95% CIs) were obtained for the difference in 
incidence and event rates, respectively. Body weight and dose were analysed in a similar manner 
to the continuous efficacy outcomes. The NNH was calculated using the formula: 1/(proportion at 
risk of hypoglycaemia with NPH insulin minus proportion at risk of hypoglycaemia using Gla-
100.. Predicted hypoglycaemic event rates per patient-year were obtained for HbA1c values 
reported at endpoint using meta-regression techniques. Regression coefficients for HbA1c (at 
endpoint), age, baseline BMI, and duration of diabetes were first estimated using a negative 
binomial regression model of event rates. Raw population averages for the treatment arm were 
calculated for age, BMI and duration of diabetes, which were then used as constant values in the 
prediction model that also included the estimated regression coefficients. 
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3. Results 
3.1. Study Population 
A total of 2091 subjects were included in the analysis. Of these, 1024 were treated with Gla-100 
and 1067 with NPH insulin. Baseline characteristics are presented in Supplementary Table 2. 
Subjects in the overall Gla-100 and NPH insulin groups were similar in terms of age, sex, body 
weight, and disease characteristics. Subjects receiving a concomitant sulfonylurea in both the 
Gla-100 and NPH insulin groups had a longer duration of diabetes, higher HbA1c and FPG at 
baseline, but a lower BMI than those receiving concomitant metformin plus a sulfonylurea. 
 
3.2. Efficacy 
The addition of Gla-100 and NPH insulin to the two OAD regimens led to reductions in HbA1c 
and FPG from baseline to Week 24 (Table 1), with the vast majority of the effect occurring in the 
first 12 weeks of treatment. Reductions in mean HbA1c and FPG at Week 24 were similar with 
Gla-100 and NPH insulin regardless of the concomitant OAD received. Similar reductions in 
HbA1c and FPG were achieved with both basal insulins during the titration phase and the 
maintenance phase irrespective of the background OADs (Table 1). The proportion of subjects 
achieving HbA1c and FPG goals over the whole treatment period and the titration and 
maintenance phases of the study was similar with Gla-100 compared with NPH insulin, though 
there was a trend for more subjects treated with Gla-100 achieving FPG ≤100mg/dL (P=0.135) 
(Supplementary Table 3). Subjects adding Gla-100 to background metformin plus a sulfonylurea 
were significantly more likely to reach the FPG target than those adding NPH insulin over the 
whole treatment period (P=0.009), and over the maintenance phase (P=0.0037) (Supplementary 
Table 3). The higher proportion of subjects achieving HbA1c goals was driven by a greater 
proportion of subjects achieving HbA1c <7.0% and <6.5% when Gla-100 was added to 
background metformin plus a sulfonylurea compared with the addition of NPH insulin to 
metformin plus a sulfonylurea (Supplementary Table 3).  
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3.3 Hypoglycaemia  
Adjusted incidences of overall, nocturnal, and severe hypoglycaemia in the overall treatment 
groups and by concomitant OAD during the whole treatment period (Fig. 1), the titration phase 
(Supplementary Fig. 1), and the maintenance phase (Supplementary Fig. 2) of the study are 
presented. Adjusted event rates of overall, nocturnal, and severe hypoglycaemia overall and by 
concomitant OAD during the entire treatment period (Supplementary Fig. 3), the titration phase 
(Supplementary Fig. 4), and the maintenance phase (Supplementary Fig. 5) of the study are 
presented.  
 
Both the incident and event rates of overall and nocturnal hypoglycaemia were consistently lower 
with Gla-100 than with NPH insulin, regardless of the background OAD regimen. The difference 
between the two basal insulins reached statistical significance for many comparisons, particularly 
for nocturnal hypoglycaemia. In general, during the whole treatment period, treatment with either 
Gla-100 or NPH insulin added to background metformin plus a sulfonylurea was associated with 
numerically higher incidence and event rates of overall and nocturnal hypoglycaemia compared 
with either basal insulin added to a sulfonylurea alone. A similar pattern was observed in both the 
titration and maintenance phases of the study. Severe hypoglycaemia was rare across both 
treatment groups, with no difference observed in incidence or event rates of severe 
hypoglycaemia between subjects treated with Gla-100 or NPH insulin.  
 
3.4 Composite endpoints 
There was no significant difference in the proportion of subjects receiving Gla-100 or NPH 
insulin achieving HbA1c <7.0% without hypoglycaemia (with plasma glucose <70 mg/dL and 
<56 mg/dL) overall, and regardless of concomitant OAD taken (Supplementary Table 4). 
However, those subjects initiating Gla-100 were more likely to achieve HbA1c <7.0% without 
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nocturnal hyperglycaemia (with plasma glucose <70 mg/dL and <56 mg/dL), predominantly 
because of the significant difference in the proportion of subjects with Gla-100 added to 
background metformin plus a sulfonylurea achieving HbA1c <7.0% without nocturnal 
hyperglycaemia (Supplementary Table 5). Subjects given Gla-100 also were significantly more 
likely to achieve FPG targets ≤100 mg/dL without overall hypoglycaemia (plasma glucose <56 
mg/dL) or nocturnal hyperglycaemia (plasma glucose <70 mg/dL and <56 mg/dL). This 
difference was again determined by the significant differences observed in those adding Gla-100 
to background metformin plus a sulfonylurea (Supplementary Tables 4 and 5). 
 
Differences between subjects treated with Gla-100 and NPH insulin were also apparent when the 
relationship of hypoglycaemia (plasma glucose <70 mg/dL) with endpoint HbA1c was assessed 
using meta-regression techniques (Fig. 2). At the lower range of HbA1c levels, the modelled rates 
of overall and nocturnal hypoglycaemia increased, and were consistently higher in those subjects 
treated with NPH insulin, although the differences for both overall and nocturnal hypoglycaemia 
were less apparent when the plasma glucose cut-off was <56 mg/dL. 
 
3.5 Body Weight  
Body weight increased in both overall treatment groups. The weight gain in the Gla-100 group 
from baseline to Week 24 was significantly higher than that observed in the NPH insulin group 
(+2.7 kg vs +2.3 kg, respectively; P=0.009). This was largely due to greater weight gain in the 
groups that added Gla-100 or NPH insulin to a background sulfonylurea only. Most of this weight 
gain occurred in the titration phase of the study (+1.6 kg for Gla-100 vs +1.4 kg for NPH insulin; 
P=0.032). Mean body weight increase from baseline to Week 24 was lower in subjects adding 
Gla-100 or NPH insulin to background metformin plus a sulfonylurea compared with adding to a 
background sulfonylurea only (+1.9 kg and +1.8 kg vs +3.7 kg and +3.0 kg, respectively). 
However, subjects adding Gla-100 or NPH insulin to a background sulfonylurea had a lower 
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weight at baseline than those adding to background metformin plus a sulfonylurea (76.6 kg and 
76.0 kg vs 87.1 kg and 87.4 kg, respectively). 
 
3.6 Insulin Dose 
Insulin dose profiles by weight over time demonstrated a higher dose requirement in subjects 
treated with Gla-100 compared with NPH insulin from approximately Week 3 onwards (Fig. 3). 
At the end of the titration phase, insulin dose was significantly higher with Gla-100 compared 
with NPH insulin (0.38 IU/kg vs 0.35 IU/kg, P=0.001; Fig. 3). Subjects adding Gla-100 and NPH 
insulin to a background sulfonylurea had a higher insulin dose requirement at baseline and at 
Week 12 and Week 24 compared with those adding Gla-100 and NPH insulin to background 
metformin plus a sulfonylurea (Fig. 3). 
 
3.7 Number needed to harm analysis 
For NPH insulin versus Gla-100 in the overall treatment period, the NNH for overall 
hypoglycaemia with plasma glucose <70 mg/dL was 25, and for plasma glucose <56 mg/dL was 
20 (Fig. 1). For overall hypoglycaemia with plasma glucose <70 mg/dL and <56 mg/dL by 
concomitant OAD, the NNH with NPH insulin versus Gla-100 was higher in those subjects 
treated with metformin plus a sulfonylurea (30 and 26, respectively) compared with a 
sulfonylurea alone (19 and 15, respectively). For nocturnal hypoglycaemia, the NNH with plasma 
glucose <70 mg/dL was 12 and with plasma glucose <56 mg/dL was 18. Similar to the 
observations for overall hypoglycaemia, the NNH for nocturnal hypoglycaemia with plasma 
glucose <70 mg/dL was higher in those treated with metformin plus a sulfonylurea compared 
with a sulfonylurea alone (14 vs 8) but was similar for the plasma glucose <56 mg/dL cut-off (20 
vs 21). NNH overall and according to concomitant OAD in the titration and maintenance phases 
of the study are presented in Supplementary Fig. 1 and Supplementary Fig. 2, respectively. The 
NNH with NPH insulin versus Gla-100 for overall and nocturnal hypoglycaemia was generally 
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lower during the titration phase compared with the maintenance phase, and where insulin was 
added to a sulfonylurea alone.  
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4. Discussion 
In this analysis of standardised, subject-level data from four randomised, controlled, treat-to-
target trials of people with T2DM inadequately controlled on a sulfonylurea or metformin plus a 
sulfonylurea, the addition of Gla-100 or NPH insulin at bedtime to existing OADs resulted in 
similar reductions in HbA1c and FPG, regardless of the concomitant OAD. The majority (>90%) 
of treatment effect in terms of HbA1c reduction was achieved by Week 12 and sustained or 
slightly improved by Week 24. At Week 12 and Week 24, the median insulin doses were 29.0 U 
and 32.0 U, respectively, for Gla-100, and 26.0 U and 30.0 U, respectively, for NPH insulin. 
Initiation of Gla-100 allowed a similar proportion of participants to achieve HbA1c and FPG 
targets during the whole treatment period compared with those initiated on NPH insulin with 
consistently lower rates of overall and nocturnal hypoglycaemia compared with NPH insulin, 
regardless of background OAD therapy. In terms of the effect of background therapy, the 
combination of Gla-100 or NPH insulin with metformin plus a sulfonylurea resulted in a higher 
proportion of subjects achieving HbA1c and FPG targets during the whole treatment period, the 
titration phase, and the maintenance phase than those adding Gla-100 or NPH insulin to a 
sulfonylurea alone. However, this was associated with a higher incidence and rate of overall and 
nocturnal hypoglycaemia in those treated with concomitant metformin plus a sulfonylurea versus 
a sulfonylurea alone. Although body weight increased in both groups, mostly in the titration 
phase, weight increases were greater with Gla-100, possibly reflecting the greater insulin dose 
requirement in the Gla-100 treatment group. Greater increases in weight from baseline were 
observed in participants who added Gla-100 or NPH insulin to a sulfonylurea alone compared 
with those adding to metformin plus a sulfonylurea, again reflecting higher insulin dose 
requirements in those treated with a sulfonylurea-only regimen and a lower initial body weight in 
this group. 
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The homogeneity of the 4 studies eligible for inclusion in this subject-level meta-analysis was 
tested by including the interaction terms between study and treatment in the models utilised for 
the analysis; these were not significant for the sulfonylurea only and metformin plus a 
sulfonylurea groups. Furthermore, hypoglycaemia incidence and event rates by treatment group 
were reviewed by study; these were lower with Gla-100 compared with NPH for most types of 
hypoglycaemia in the 4 studies. For nocturnal hypoglycaemia in particular, the incidence and 
event rates were all lower with Gla-100 compared with NPH in all 4 studies (data not shown). 
 
The overall data presented here are supportive of previous meta-analyses and subject-level 
analyses comparing glycaemic control and hypoglycaemia outcomes between Gla-100 and NPH 
insulin [7, 15, 16]. Similar to our findings, the most recent Cochrane review meta-analysis 
comparing Gla-100 and NPH insulin treatment in T2DM reported that HbA1c did not differ in a 
clinically relevant way between treatment groups (weighted mean difference from baseline to 
endpoint 0.1% [95% CI –0.1 to 0.2], P=0.49 in favour of NPH insulin for four studies with 
relevant data) [16]. However, in the three studies with available data included in this analysis, 
symptomatic overall hypoglycaemia and symptomatic nocturnal hypoglycaemia were 
significantly lower for Gla-100 compared with NPH insulin (relative risk 0.84 [95% CI 0.75 to 
0.95]; P=0.005 and 0.66 (0.55 to 0.80); P<0.000, respectively) [16]. Two previous subject-level 
analyses have also reported significantly lower rates of hypoglycaemia with Gla-100 compared 
with NPH insulin [7, 15]. In an analysis of all randomised phase III and IV clinical trials 
comparing Gla-100 and NPH insulin sponsored by the manufacturer of Gla-100 as of 2004 (six 
studies in T2DM), unadjusted rates of symptomatic, confirmed, and severe hypoglycaemic events 
(events per 100 patient-days) were 13.67%, 39.34%, and 53.73% lower, respectively, with Gla-
100 compared with NPH insulin (P<0.05) [15]. The risk of nocturnal hypoglycaemia was reduced 
by approximately 50% with Gla-100 versus NPH insulin (OR 0.44–0.52; P<0.001–0.0047) in a 
pooled analysis of subject-level data from subjects treated with once-daily evening Gla-100 or 
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NPH insulin [7]. In this study, it was estimated that eight people with T2DM needed to use Gla-
100 rather than NPH insulin to avoid one additional person from experiencing a symptomatic 
nocturnal hypoglycaemic event during a median of 24 weeks of treatment [7].  
 
Hypoglycaemia has substantial clinical impact on morbidity and quality of life, and has been 
associated with increased mortality [2, 17]. Fear of hypoglycaemia, and particularly nocturnal 
hypoglycaemia, by both clinicians and people with diabetes can contribute to a delay in starting 
insulin therapy, timely insulin intensification, and treatment adherence [6, 17, 18], all of which 
present major barriers to achieving good glycaemic control. Therefore the achievement of 
appropriate glycaemic control whilst at the same time minimising hypoglycaemia, particularly 
nocturnal hypoglycaemia, is a key priority in the management of T2DM. 
 
It should be noted that three of the seven studies that were originally identified for this subject-
level meta-analysis were excluded [8, 9, 13]. Studies 3002 and 3006 [8, 9] did not utilise the 
treat-to-target concept (the titration target was 80-140 mg/dL) and study 4012 [13] had an FPG 
target of <120 mg/dL. As predefined FPG targets in a study potentially affect efficacy and safety 
outcomes, our objective was to analyse only treat-to-target studies with the same FPG target of 
<100 mg/dL to avoid potential bias from different targets which may “dilute” the impact of a pre-
specified FPG target as titration procedures and dose adjustments are mainly driven by the FPG 
target set in the study. Previous subject-level analyses [7, 15] have included treat-to-target and 
non-treat-to-target studies and did not consider such titration effects varying between the studies. 
Furthermore, two of the studies did not have HbA1c available data at Week 24 and did not target 
an insulin naïve population [8, 9]. The excluded studies showed broadly similar results to those 
shown in this subject-level meta-analysis and if study 4012 [13] were to be included in the 
analysis, both efficacy and safety results would be expected to be consistent with those already 
obtained. Briefly, in these studies HbA1c reductions in subjects treated with Gla-100 and NPH 
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were comparable, with one study demonstrating superiority with Gla-100 [13]. All three studies 
showed significantly reduced rates of nocturnal hypoglycaemia in Gla-100 treated subjects, while 
one also showed lower overall and severe hypoglycaemia [13]. Weight gain was either 
comparable between Gla-100 and NPH [8], lower in subjects treated with Gla-100 [9] or not 
reported [13].  
 
Compared with the earlier subject-level analyses conducted by Mullins et al. [15] and Home et al. 
[7], our analysis has several additional strengths. We included only those studies which utilised 
standardised protocol-driven titration regimens and treatment targets, and in which Gla-100 and 
NPH insulin were given only at bedtime. Furthermore, all of the derived subject-level data were 
standardised, permitting consistent endpoint definitions to be applied across the studies. Finally, 
the subject-level analysis permitted inclusion of baseline characteristics as covariates in the 
analyses. The analysis is, however, limited by the lack of a metformin-only comparator group and 
subjects using other OADs, including TZDs, DPP-4 inhibitors, or SGLT2 inhibitors. Had a 
metformin-only arm been available for analysis, in line with previous data, one might expect 
improved outcomes, including lower rates of hypoglycaemia and less weight gain, compared with 
the results of this analysis [6, 19].  
 
In summary, this subject-level analysis supports existing data in finding that Gla-100 is associated 
with achievement of similar levels of glycaemic control as NPH insulin when both are given 
once-daily at bedtime. There is a lower risk of overall and particularly nocturnal hypoglycaemia, 
with Gla-100 despite higher insulin requirements and greater weight gain. Subjects adding Gla-
100 to a background regimen of metformin plus a sulfonylurea are more likely to have better 
outcomes in terms of glycaemic control and weight gain, but a slightly higher risk of 
hypoglycaemia.  
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Table 1 - Glycaemic control as illustrated by change in HbA1c and FPG between baseline, Week 12, and Week 24 overall and by 
concomitant OAD.  
Data represent mean ± standard deviation. P values were obtained from an Analysis of Covariance (ANCOVA) model with baseline value 
as covariate and treatment arm and OAD group as factors. MET, metformin; SU, sulfonylurea.  
 Gla-100 NPH insulin 
P 
value 
Gla-100 + SU 
NPH insulin + 
SU 
P 
value 
Gla-100 + 
MET + SU 
NPH insulin + 
MET + SU 
P  
value 
HbA1c, %          
Baseline n = 1006 n = 1045  n = 434 n = 462  n = 572 n = 583  
 8.7 (1.0) 8.7 (1.0)  9.0 (1.0) 9.1 (1.0)  8.3 (0.9) 8.3 (0.9)  
Change from baseline to Week 12 n = 987/1006 n = 1028/1045  n = 430/434 n = 456/462  n = 557/572 n = 572/583  
 –1.2 (1.0) –1.1 (1.0) 0.190 –1.2 (1.2) –1.1 (1.2) 0.076 –1.2 (0.9) –1.2 (0.9) 0.875 
Change from baseline to Week 24 n = 1006 n = 1045  n = 434 n = 462  n = 572 n = 583  
 –1.3 (1.1) –1.2 (1.1) 0.184 –1.2 (1.3) –1.1 (1.3) 0.161 –1.3 (1.0) –1.3 (1.0) 0.421 
FPG, mg/dL          
Baseline n = 1002 n = 1038  n = 438 n = 470  n = 564 n = 568  
 192.6 (55.9) 190.1 (55.2)  209.8 (60.1) 207.2 (59.4)  178.9 (48.1) 175.7 (46.6)  
Change from baseline to Week 12 n = 984/1002 n = 1020/1038  n = 437/438 n = 468/470  n = 547/564 n = 552/568  
 –75.5 (62.2) –72.1 (59.3) 0.426 –92.2 (68.6) –87.9 (64.5) 0.449 –62.2 (53.0) –58.7 (50.8) 0.732 
Change from baseline to Week 24 n = 1002 n = 1038  n = 438 n = 470  n = 564 n = 568  
 –75.7 (61.6) –72.5 (59.5) 0.553 –90.4 (67.3) –87.4 (66.0) 0.832 –64.3 (54.2) –60.2 (50.3) 0.546 
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Fig. 1 – Adjusted incidence of hypoglycaemia between baseline and Week 24 in the overall treatment groups (a), the concomitant 
sulfonylurea group (b), and the concomitant metformin plus a sulfonylurea group (c). NPH, neutral protamine Hagedorn insulin; PG, 
plasma glucose. 
A 
 
  
 24 
B 
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C 
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Fig. 2 – Modelled adjusted overall (plasma glucose <70 mg/dL [a] and plasma glucose <56 mg/dL [b]) and nocturnal (plasma glucose <70 
mg/dL [c] and plasma glucose <56 mg/dL [d]) hypoglycaemia event rates for HbA1c values reported at endpoint. 
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Fig. 3 – Insulin dose profiles by weight (U/kg) over time in subjects treated with Gla-100 or NPH insulin overall and according to 
background oral therapy. Gla-100, insulin glargine 100 U/mL; MET, metformin; NPH, neutral protamine Hagedorn; SU, sulfonylurea. 
 
 28 
Supplementary materials 
Supplementary Table 1 – Key characteristics of included and excluded studies of Gla-100 vs NPH insulin. 
Study Phase Acronym [Ref] Treatment Subjects (N) Treatment period  
(weeks) 
Insulin titration  
schedule 
Included studies: Treat-to-target (FPG ≤100 mg/dL) 
4001 IIIb FLEXIBLE [10] 
 
Morning vs bedtime Gla-100 + morning glimepiride 
vs bedtime NPH insulin + morning glimepiride 
697 24 Weekly 
4002 IIIb TTT [11] 
 
Gla-100 bedtime + OADs 
vs NPH insulin bedtime + OADs 
756 24 Weekly 
4013 IIIb Latin America [12] 
 
Gla-100 bedtime + morning glimepiride 
vs NPH insulin bedtime + morning glimepiride 
481 24 Weekly 
2762 IIIb/IV LANCELOT [14] 
 
Gla-100 bedtime + metformin ± sulfonylurea  
vs NPH insulin bedtime + metformin ± sulfonylurea 
704 36 Weekly 
Excluded studies: Not treat-to-target (FPG >100 mg/dL) 
3002 
 
III 
 
3002 [8] 
 
Bedtime Gla-100 + OADs  
vs bedtime NPH insulin + OADs  
422  52  Weekly  
 29 
3006  
 
III 
 
3006 [9] 
 
Once-daily Gla-100 at bedtime  
vs once-daily or twice-daily NPH insulin  
518 28  Weekly  
4012  
 
IIIb/IV 
 
LEAD [13] 
 
Gla-100 bedtime + morning glimepiride  
vs NPH insulin bedtime + morning glimepiride  
443 24  Weekly  
FPG, fasting plasma glucose; Gla-100, insulin glargine 100 U/mL; NPH, neutral protamine Hagedorn; OAD, oral antidiabetes drug. 
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Supplementary Table 2 – Baseline demographic characteristics overall and by concomitant OAD. 
Characteristic Gla-100 
(n=1024) 
NPH insulin 
(n=1067) 
Gla-100 + SU 
(n=440) 
NPH insulin + SU 
(n=472) 
Gla-100  
+ MET + SU 
(n=584) 
NPH insulin 
+ MET + SU 
(n=595) 
Age, years 57.5 (9.2) 58.1 (8.8) 58.3 (9.7) 59.3 (9.5) 56.9 (8.7) 57.2 (8.2) 
Male, n (%) 502 (49.0) 517 (48.5) 223 (50.7) 210 (44.5) 279 (47.8) 307 (51.6) 
Diabetes duration, 
 years 
9.3 (6.1) 9.9 (5.9) 9.6 (6.7) 10.2 (6.2) 9.1 (5.7) 9.7 (5.7) 
Body weight, kg 82.6 (17.3) 82.4 (17.1) 76.6 (14.2) 76.0 (15.2) 87.0 (18.1) 87.5 (16.8) 
BMI, kg/m
2
 29.6 (4.6) 29.6 (4.6) 27.9 (3.9) 28.0 (4.1) 30.9 (4.8) 30.9 (4.7) 
HbA1c, % 8.6 (1.0) 8.7 (1.0) 9.0 (1.0) 9.1 (1.1) 8.3 (0.9) 8.4 (0.9) 
FPG, mg/dL
a
 192.1 (55.6) 189.3 (55.1) 209.8 (60.0) 206.8 (59.5) 178.5 (47.8) 174.9 (46.7) 
Data represent mean (standard deviation) unless otherwise stated. 
a
Denominator for FPG at baseline: n=1013 for Gla-100 overall; n=1047 for NPH insulin overall; n=440 for Gla-100 plus sulfonylurea; n=471 for NPH insulin 
plus sulfonylurea; n=573 for Gla-100 plus metformin plus sulfonylurea; n=576 for NPH insulin plus metformin plus sulfonylurea. BMI, body mass index; FPG, 
fasting plasma glucose; Gla-100, insulin glargine 100 U/mL; HbA1c, glycated haemoglobin; MET, metformin; NPH, neutral protein Hagedorn; OAD, oral 
antidiabetes drug; SU, sulfonylurea.  
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Supplementary Table 3 – Proportion of subjects achieving target HbA1c <7.0% or <6.5% or FPG ≤100 mg/dL during the whole 
treatment period, the titration phase, and the maintenance phase, overall and by concomitant OAD. 
 
Gla-100 NPH insulin Relative 
risk 
(95% CI) 
P value 
Gla-100 + 
SU 
NPH insulin 
+ SU 
Relative 
risk 
(95% CI) 
P value 
Gla-100 + 
MET + SU 
NPH insulin 
+ MET + 
SU 
Relative 
risk 
(95% CI) 
P value 
Whole treatment period (Week 0–24) 
HbA1c <7.0%, n (%) 377 (38.0) 377 (36.6) 1.03 
(0.93 to 1.13) 
0.603 
91 (21.3) 100 (21.7) 1.03 
(0.82 to 1.30) 
0.801 
286 (50.7) 277 (48.5) 1.03 
(0.93 to 1.14) 
0.571 
HbA1c <6.5%, n (%) 191 (19.0) 170 (16.3) 1.16 
(0.97 to 1.38) 
0.109 
51 (11.8) 43 (9.3) 1.27 
(0.88 to 1.84) 
0.199 
140 (24.5) 127 (21.8) 1.14 
(0.93 to 1.39) 
0.200 
FPG ≤100 mg/dL, n 
(%) 
363 (36.9) 344 (33.8) 1.09 
(0.97 to 1.23) 
0.135 
153 (35.3) 174 (37.5) 0.95 
(0.80 to 1.13) 
0.580 
210 (38.0) 170 (30.7) 1.24 
(1.06 to 1.46) 
0.009 
Titration phase (Week 0–12) 
HbA1c <7.0%, n (%) 308 (31.6) 324 (32.0) 1.03 
(0.93 to 1.15) 
0.545 
77 (18.1) 95 (20.9) 0.87 
(0.66 to 1.13) 
0.295 
231 (42.1) 229 (40.9) 1.01 
(0.91 to 1.12) 
0.845 
HbA1c <6.5%, n (%) 137 (13.9) 116 (11.3) 1.23 
(0.99 to 1.53) 
0.068 
41 (9.6) 38 (8.3) 1.15 
(0.75 to 1.75) 
0.524 
96 (17.2) 78 (13.6) 1.27 
(0.98 to 1.65) 
0.070 
FPG ≤100 mg/dL, n 
(%) 
350 (36.2) 337 (33.7) 1.07 
(0.95 to 1.21) 
0.242 
165 (38.2) 178 (38.5) 1.00 
(0.84 to 1.18) 
0.969 
185 (34.5) 159 (29.6) 1.18 
(0.99 to 1.40) 
0.066 
Maintenance phase (Week 12–24) 
HbA1c <7.0%, n (%) 110 (16.9) 115 (17.0) 0.97 
(0.78 to 1.20) 
0.775 
32 (9.5) 32 (9.2) 1.04 
(0.65 to 1.66) 
0.873 
78 (24.8) 83 (25.2) 1.00 
(0.79 to 1.27) 
0.978 
HbA1c <6.5%, n (%) 87 (10.5) 76 (8.5) 1.28 
(0.98 to 1.68) 
0.070 
20 (5.3) 16 (3.9) 1.36 
(0.71 to 2.58) 
0.352 
67 (14.7) 60 (12.3) 1.26 
(0.94 to 1.70) 
0.117 
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FPG ≤100 mg/dL, n 
(%) 
170 (27.9) 178 (26.9) 1.06 
(0.89 to 1.27) 
0.507 
59 (23.1) 76 (28.1) 0.80 
(0.60 to 1.06) 
0.126 
111 (31.4) 102 (26.1) 1.27 
(1.01 to 1.58) 
0.0037 
Category of subjects achieving HbA1c/FPG target was limited to subjects with baseline (or Week 12 baseline) level above target. CI, confidence interval; FPG, 
fasting plasma glucose; Gla-100, insulin glargine 100 U/mL; HbA1c, glycated haemoglobin; MET, metformin; NPH, neutral protein Hagedorn; OAD, oral 
antidiabetes drug; SU, sulfonylurea. 
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Supplementary Table 4 – Proportion of subjects achieving target HbA1c <7.0% or FPG ≤100 mg/dL without overall hypoglycaemia 
during the whole treatment period, the titration phase, and the maintenance phase, overall and by concomitant OAD. 
 Gla-100 NPH insulin Relative 
risk 
(95% CI) 
P value 
Gla-100 + 
SU 
NPH insulin 
+ SU 
Relative 
risk 
(95% CI) 
P value 
Gla-100 + 
MET + SU 
NPH insulin 
+ MET + 
SU 
Relative 
risk 
(95% CI) 
P value 
Whole treatment period (Week 0–24) 
HbA1c <7.0% without 
overall hypoglycaemia 
PG <70 mg/dL, n (%) 
118 (11.9) 114 (11.1) 1.06 
(0.83 to 1.34) 
0.653 
40 (9.3) 41 (8.9) 1.07 
(0.72 to 1.59) 
0.735 
78 (13.8) 73 (12.8) 1.05 
(0.78 to 1.40) 
0.762 
HbA1c <7.0% without 
overall hypoglycaemia 
PG <56 mg/dL, n (%) 
208 (21.0) 198 (19.2) 1.08 
(0.91 to 1.27) 
0.396 
69 (16.1) 60 (13.0) 1.30 
(0.97 to 1.74) 
0.080 
139 (24.6) 138 (24.2) 1.00 
(0.81 to 1.22) 
0.963 
FPG ≤100 mg/dL 
without overall 
hypoglycaemia PG <70 
mg/dL, n (%) 
129 (13.1) 116 (11.4) 1.16 
(0.92 to 1.47) 
0.209 
64 (14.8) 65 (14.0) 1.08 
(0.79 to 1.47) 
0.639 
65 (11.8) 51 (9.2) 1.24 
(0.88 to 1.75) 
0.218 
FPG ≤100 mg/dL 
without overall 
hypoglycaemia PG <56 
mg/dL, n (%) 
221 (22.4) 191 (18.8) 1.20 
(1.01 to 1.42) 
0.036 
105 (24.2) 103 (22.2) 1.10 
(0.87 to 1.39) 
0.411 
116 (21.0) 88 (15.9) 1.29 
(1.00 to 1.65) 
0.046 
Titration phase (Week 0–12 ) 
HbA1c <7.0% without 
overall hypoglycaemia 
PG <70 mg/dL, n (%) 
127 (13.0) 133 (13.1) 1.01 
(1.01 to 1.26) 
0.955 
42 (9.9) 52 (11.5) 0.86 
(0.59 to 1.27) 
0.452 
85 (15.5) 81 (14.5) 1.08 
(0.82 to 1.42) 
0.585 
HbA1c <7.0% without 
overall hypoglycaemia 
PG <56 mg/dL, n (%) 
215 (22.1) 214 (21.1) 1.07 
(0.92 to 1.25) 
0.385 
64 (15.1) 72 (15.9) 0.95 
(0.70 to 1.29) 
0.743 
151 (27.5) 142 (25.4) 1.12 
(0.93 to 1.35) 
0.245 
FPG ≤100 mg/dL 
without overall 
hypoglycaemia PG <70 
mg/dL, n (%) 
158 (16.3) 132 (13.2) 1.24 
(1.00 to 1.53) 
0.046 
80 (18.5) 79 (17.1) 1.10 
(0.83 to 1.45) 
0.496 
78 (14.6) 53 (9.9) 144 
(1.04 to 1.99) 
0.028 
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FPG ≤100 mg/dL 
without overall 
hypoglycaemia PG <56 
mg/dL, n (%) 
256 (26.4) 230 (23.0) 1.15 
(0.99 to 1.34) 
0.072 
123 (28.5) 131 (28.4) 1.01 
(0.82 to 1.24) 
0.917 
133 (24.8) 99 (18.4) 1.34 
(1.06 to 1.68) 
0.013 
Maintenance phase (Week 12–24 ) 
HbA1c <7.0% without 
overall hypoglycaemia 
PG <70 mg/dL, n (%) 
64 (9.8) 52 (7.7) 1.24 
(0.89 to 1.75) 
0.208 
21 (6.3) 18 (5.2) 1.21 
(0.66 to 2.23) 
0.538 
43 (13.7) 34 (10.3) 1.35 
(0.90 to 2.04) 
0.149 
HbA1c <7.0% without 
overall hypoglycaemia 
PG <56 mg/dL, n (%) 
83 (12.7) 81 (11.9) 1.03 
(0.79 to 1.35) 
0.833 
27 (8.0) 24 (6.9) 1.17 
(0.69 to 1.98) 
0.564 
56 (17.8) 57 (17.3) 1.04 
(0.76 to 1.44) 
0.792 
FPG ≤100 mg/dL 
without overall 
hypoglycaemia PG <70 
mg/dL, n (%) 
86 (14.1) 80 (12.1) 1.17 
(0.88 to 1.55) 
0.283 
35 (13.7) 40 (14.8) 0.92 
(0.61 to 1.39) 
0.693 
51 (14.4) 40 (10.2) 1.44 
(0.98 to 2.11) 
0.064 
FPG ≤100 mg/dL 
without overall 
hypoglycaemia PG <56 
mg/dL, n (%) 
129 (21.2) 118 (17.9) 1.20 
(0.98 to 1.49) 
0.108 
50 (19.6) 54 (20.0) 0.97 
(0.69 to 1.36) 
0.854 
79 (22.3) 64 (16.4) 1.41 
(1.06 to 1.89) 
0.019 
CI, confidence interval; FPG, fasting plasma glucose; Gla-100, insulin glargine 100 U/mL; HbA1c, glycated haemoglobin; MET, metformin; NPH, neutral 
protein Hagedorn; OAD, oral antidiabetes drug; PG, plasma glucose; SU, sulfonylurea.  
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Supplementary Table 5 – Proportion of subjects achieving target HbA1c <7.0% or FPG ≤100 mg/dL without nocturnal hypoglycaemia 
during the whole treatment period, the titration phase, and the maintenance phase, overall and by concomitant OAD. 
 
Gla-100 NPH insulin Relative 
risk 
(95% CI) 
P value 
Gla-100 + 
SU 
NPH insulin 
+ SU 
Relative 
risk 
(95% CI) 
P value 
Gla-100 + 
MET + SU 
NPH insulin 
+ MET + 
SU 
Relative 
risk 
(95% CI) 
P value 
Whole treatment period (Week 0–24) 
HbA1c <7.0% without 
nocturnal 
hypoglycaemia PG <70 
mg/dL, n (%) 
245 (24.7) 209 (20.3) 1.19 
(1.02 to 1.39) 
0.032 
75 (17.5) 70 (15.2) 1.19 
(0.90 to 1.58) 
0.218 
170 (30.1) 139 (24.3) 1.20 
(0.99 to 1.45) 
0.057 
HbA1c <7.0% without 
nocturnal 
hypoglycaemia PG <56 
mg/dL, n (%) 
301 (30.3) 278 (27.0) 1.12 
(0.98 to 1.27) 
0.087 
86 (20.1) 82 (17.8) 1.21 
(0.94 to 1.55) 
0.140 
215 (38.1) 196 (34.3) 1.11 
(0.95 to 1.29) 
0.182 
FPG ≤100 mg/dL 
without nocturnal 
hypoglycaemia PG <70 
mg/dL, n (%) 
241 (24.5) 201 (19.8) 1.24 
(1.05 to 1.46) 
0.010 
115 (26.6) 116 (25.0) 1.07 
(0.86 to 1.33) 
0.528 
126 (22.8) 85 (15.4) 1.44 
(1.13 to 1.85) 
0.003 
FPG ≤100 mg/dL 
without nocturnal 
hypoglycaemia PG <56 
mg/dL, n (%) 
302 (30.7) 264 (26.0) 1.18 
(1.03 to 1.36) 
0.017 
133 (30.7) 141 (30.4) 1.02 
(0.84 to 1.24) 
0.859 
169 (30.6) 123 (22.2) 1.36 
(1.11 to 1.66) 
0.003 
Titration phase (Week 0–12) 
HbA1c <7.0% without 
nocturnal 
hypoglycaemia PG <70 
mg/dL, n (%) 
220 (22.6) 219 (21.6) 1.06 
(0.91 to 1.24) 
0.453 
66 (15.5) 72 (15.9) 0.98 
(0.72 to 1.33) 
0.893 
154 (28.1) 147 (26.3) 1.09 
(0.91 to 1.31) 
0.355 
HbA1c <7.0% without 
nocturnal 
hypoglycaemia PG <56 
mg/dL, n (%) 
276 (28.3) 267 (26.3) 1.13 
(0.99 to 1.28) 
0.062 
72 (16.9) 85 (18.7) 0.90 
(0.68 to 1.20) 
0.491 
204 (37.2) 182 (32.5) 1.19 
(1.03 to 1.38) 
0.017 
FPG ≤100 mg/dL 
without nocturnal 
267 (27.6) 216 (21.6) 1.28 
(1.10 to 1.49) 
137 (31.7) 125 (27.1) 1.18 
(0.96 to 1.44) 
130 (24.3) 91 (16.9) 1.42 
(1.12 to 1.80) 
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hypoglycaemia PG 
<mg/dL, n (%) 
0.002 0.115 0.004 
FPG ≤100 mg/dL 
without nocturnal 
hypoglycaemia PG <56 
mg/dL, n (%) 
318 (32.9) 276 (27.6) 1.19 
(1.04 to 1.36) 
0.010 
153 (35.4) 151 (32.7) 1.09 
(0.91 to 1.31) 
0.355 
165 (30.8) 125 (23.3) 1.33 
(1.09 to 1.62) 
0.005 
Maintenance phase (Week 12–24) 
HbA1c <7.0% without 
nocturnal 
hypoglycaemia PG <70 
mg/dL, n (%) 
92 (14.1) 74 (10.9) 1.26 
(0.96 to 1.65) 
0.095 
29 (8.6) 26 (7.4) 1.16 
(0.70 to 1.92) 
0.570 
63 (20.0) 48 (14.6) 1.40 
(1.01 to 1.94) 
0.044 
HbA1c <7.0% without 
nocturnal 
hypoglycaemia PG <56 
mg/dL, n (%) 
97 (14.9) 90 (13.3) 1.09 
(0.85 to 1.40) 
0.495 
31 (9.2) 28 (8.0) 1.15 
(0.71 to 1.87) 
0.575 
66 (21.0) 62 (18.8) 1.14 
(0.85 to 1.53) 
0.381 
FPG ≤100 mg/dL 
without nocturnal 
hypoglycaemia PG <70 
mg/dL, n (%) 
132 (21.7) 132 (20.0) 1.09 
(0.88 to 1.34) 
0.449 
52 (20.4) 64 (23.7) 0.84 
(0.61 to 1.16) 
0.289 
80 (22.6) 68 (17.4) 1.33 
(1.00 to 1.76) 
0.048 
FPG ≤100 mg/dL 
without nocturnal 
hypoglycaemia PG < 
56 mg/dL, n (%) 
152 (25.0) 146 (22.1) 1.14 
(0.94 to 1.39) 
0.178 
56 (22.0) 66 (24.4) 0.88 
(0.65 to 1.20) 
0.414 
96 (27.1) 80 (20.5) 1.37 
(1.07 to 1.76) 
0.014 
CI, confidence interval; FPG, fasting plasma glucose; Gla-100, insulin glargine 100 U/mL; HbA1c, glycated haemoglobin; MET, metformin; NPH, neutral 
protein Hagedorn; OAD, oral antidiabetes drug; PG, plasma glucose; SU, sulfonylurea.  
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Supplementary Fig. 1 – Adjusted incidence of hypoglycaemia between baseline and Week 12 in the overall treatment groups (a), the 
concomitant sulfonylurea group (b), and the concomitant metformin plus a sulfonylurea group (c). CI, confidence interval; Gla-100, 
insulin glargine 100 U/mL; NNH, number needed to harm; NPH, neutral protamine Hagedorn insulin. 
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Supplementary Fig. 2 – Adjusted incidence of hypoglycaemia between Week 12 and Week 24 in the overall treatment groups (a), the 
concomitant sulfonylurea group (b), and the concomitant metformin plus sulfonylurea group (c). CI, confidence interval; Gla-100, insulin 
glargine 100 U/mL; NNH, number needed to harm; NPH, neutral protamine Hagedorn insulin. 
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Supplementary Fig. 3 – Adjusted hypoglycaemia event rate between baseline and Week 24 in the overall treatment groups (a), the 
concomitant sulfonylurea group (b), and the concomitant metformin plus a sulfonylurea group (c). 
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Supplementary Fig. 4 – Adjusted hypoglycaemia event rate between baseline and Week 12 in the overall treatment groups (a), the 
concomitant sulfonylurea group (b), and the concomitant metformin plus a sulfonylurea group (c). CI, confidence interval; Gla-100, 
insulin glargine 100 U/mL; NNH, number needed to harm; NPH, neutral protamine Hagedorn insulin.  
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Supplementary Fig. 5 – Adjusted hypoglycaemia event rate between Week 12 and Week 24 in the overall treatment groups (a), in the 
concomitant sulfonylurea group (b), and in the concomitant metformin plus a sulfonylurea group (c). CI, confidence interval; Gla-100, 
insulin glargine 100 U/mL; NNH, number needed to harm; NPH, neutral protamine Hagedorn insulin. 
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